Background A cancer stem cell model was proposed for bladder carcinoma, as there is a subpopulation of tumor cells capable of resisting conventional therapies and surviving treatment to facilitate recurrence and metastasis. Oct-4 is a pluripotency marker of stem cells, which has been found to be associated with worse prognosis in multiple somatic tumors.Aim We aimed to explore the expression of Oct-4 protein in urothelial carcinoma and some of its variants and also determine whether Oct-4 expression and level of expression are associated with the clinicopathological parameters such as age, sex, grade, stage, morphology, and tumor progression.Patients and methods We tested 84 urothelial tumor specimens including all grades, stages, and some variants of urothelial carcinoma for the expression of Oct-4. Two sections were prepared per case for histologic evaluation and immunohistochemical staining by Oct-4 monoclonal antibody. The immunostaining was evaluated semiquantitavely through obtaining an H-score for each case.Results All cases took up the Oct-4 stain except for low-grade tumors and carcinoma in-situ cases. The highest percentage of positive cases was seen in invasive urothelial carcinoma with variant morphology other than conventional (19.1%). Presence of Oct-4 expression was significantly associated with grade (P=0.03), histopathologic type of urothelial tumor (P<0.001), category (P<0.001), and tumor progression (P=0.001). Conversely, the level of Oct-4 expression among positive cases was not found to be associated with any of the studied parameters.Conclusion Our study calls for considering Oct-4 as a novel marker of prognostic significance that could be implemented in target therapies for urothelial carcinoma.
Microsatellite instability (MSI) is the genetic pathway underlying 15% of sporadic colorectal carcinoma (CRC) and hereditary non-polyposis CRC. MSI-H CRC has a distinct clinicopathological characteristic including excess mucin and signet ring component, proximal colon, Crohn's like reaction, lymphocytic infiltration, and better survival.
AIM: Prostate cancer (PCa) is the second most common cancers in men worldwide. Its incidence can be influenced by several risk factors including genetic susceptibility. Therefore the search for the expression of a certain gene (ERG) and its rearrangement could give us clues for proper identification of PCa. And the study of ERG expression and its comparison to FISH in Egyptian patients can show whether ERG immunophenotype could be used instead of FISH, as it is cheaper.MATERIALS AND METHODS: This study was performed on 85 cases of PCa, showing 30 cases with HGPIN and 30 cases of prostatic hyperplasia. All were immunohistochemistry stained using ERG monoclonal rabbit antihuman antibody was used (clone: EP111). FISH analysis was performed in 38 biopsies of PCa cases to detect TMRPSS2-ERG rearrangement using the FISH ZytoLight TriCheck Probe (SPEC TMRPSS2-ERG).RESULTS: ERG expression was found in 26% of PCa cases and 20% of HGPIN cases. FISH analysis showed fusion of 21 cases of PCa (out of 22 cases showing ERG immunoexpression).CONCLUSION: Our findings emphasise that only malignant and pre-malignant cells and not benign cells from the prostate stain positive. ERG expression may offer a simpler, accurate and less costly alternative for evaluation of ERG fusion status in PCa.
The present study was undertaken to development of BHK-21 cell adapted inactivated vaccine of Newcastle disease virus (NDVgenotype VII) from the field isolate from broiler chicken in Egypt during 2015-2016.The isolatesof El-Giza/2015were classified by sequencing as velogenic NDV genotype VII d contains F protein cleavage site motifs (112RRQKRF117).Such virus was propagated in the BHK-21 cell line.and cell adapted virus was confirmed as NDV by reverse transcription-polymerase chain reaction (RT-PCR) using fusion gene-specific primers and used to develop inactivated vaccine adjuvanted with Montanide IMS 1313.Potency test revealed that Vaccinated chicks with 0.5ml of prepared NDV vaccine exhibited HI antibody titer of 8.6 log2 three weeks post vaccination with the highest titer (10.6 log2/ml) at the 6th-week post vaccination, and 3rd weeks post challenge test.Protective antibodies values were persisting till 12th weeks post vaccination.All chicken groups vaccinated with both prepared inactivated tissue culture vaccine using ISA 1313 and VSVRI inactivated ISA70 adjuvant vaccines were passed challenge test (97.5%,97%,96%protective efficiency to SPF chickens) against the isolated virulent NDV, while the control group could not provide any protective efficiency.The present study indicated that, BHK-21 cell adapted recent isolated NDV inactivated vaccine produced a satisfactory antibodies titre that efficient in control of the disease in Egypt.